BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe

The experimental drug, acoramidis, is being developed as an oral treatment for transthyretin amyloid cardiomyopathy, in which abnormal deposits of a protein called amyloid build up in the heart and can cause the organ to fail.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/uOL2seA
via